X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol
Therapeutic Area: Musculoskeletal Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 18, 2024
Details:
RHO Phyto Micro Drop 100, a 10% CBD (THC free) is a proprietary oral formulation of cannabidiol, which is a CB1 receptor negative allosteric modulator. It is indicated for the treatment of seizures related to Lennox-Gastaut Syndrome and Dravet Syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Trunerox (cannabidiol) is a CB1 receptor negative allosteric modulator, which is approved for the treatment of patients with dravet syndrome and lennox-gastaut syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Trunerox
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The exclusive supply agreement is for the Company’s proprietary topical products that have been commercialized in the Canadian market under the RHO Phyto brand, including AVCN-583601, Ultra-CBD cream, a CBD localized cream developed to target dermatology conditions.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: AVCN-583601
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 05, 2024
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Details:
Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MediPharm Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 26, 2023
Details:
The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Research Centre at Langara College
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Details:
The research collaboration will explore the efficacy of Avicanna’s drug candidates including AVCN319302 in animal models for Epilepsy. In addition, the research collaboration will evaluate the anti-seizure properties of rare cannabinoids in isolation and in combination.
Lead Product(s): AVCN319302,Cannabidiol
Therapeutic Area: Neurology Product Name: AVCN319302
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Toronto
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 15, 2022
Details:
Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Psilly
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ei.Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
